SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

GlaxoSmithkline Consumer Healthcare surges on reporting 37% rise in Q3 net profit

09 Feb 2016 Evaluate

Glaxosmithkline Consumer Healthcare is currently trading at Rs. 5873.30, up by 53.00 points or 0.91% from its previous closing of Rs. 5820.30 on the BSE.

The scrip opened at Rs. 5821.00 and has touched a high and low of Rs. 5900.00 and Rs. 5821.00 respectively. So far 23 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6800.00 on 23-Dec-2015 and a 52 week low of Rs. 5580.00 on 25-Jan-2016.

Last one week high and low of the scrip stood at Rs. 5900.00 and Rs. 5696.65 respectively. The current market cap of the company is Rs. 24477.58 crore.

The promoters holding in the company stood at 72.46% while Institutions and Non-Institutions held 12.66% and 14.90% respectively.

GlaxoSmithkline Consumer Healthcare has registered a rise of 36.76% in its net profit at Rs 131.85 crore in Q3FY16 as compared to Rs 96.41 crore in the corresponding quarter previous year. The total income of the company has increased marginally by 1.78% to Rs 1086.32 crore for the quarter under review as compared to Rs 1067.27 crore in the same quarter last year.

GlaxoSmithKline Consumer Healthcare is a subsidiary of GlaxoSmithKline plc of UK. GlaxoSmithkline Consumer Healthcare’s core business is manufacturing of health drinks under the brand Horlicks. It exports products to countries like Bangladesh, Myanmar, Sri Lanka, Middle East, Fiji, Mauritius, Nepal, Bhutan and many more.

Glaxo.Cons. Health Share Price

9696.40 0.00 (0.00%)
15-Apr-2020 18:01 View Price Chart
Peers
Company Name CMP
Varun Beverages 452.00
Nestle 1251.90
Britannia Inds 5590.00
LT Foods 418.00
Hatsun Agro Product 940.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×